News

January 29, 2021
Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate
October 13, 2020
Asahi Kasei Pharma to solicit proposals for drug discovery research
June 2, 2020
Asahi Kasei Pharma obtains Chinese approval for Flivas™ (naftopidil) dysuria treatment
March 19, 2020
Asahi Kasei Pharma concludes license agreement with SBI Biotech for SBI-3150
January 9, 2020
Denial of motion for preliminary injunction requesting continuous supply of XIAFLEX® injection
November 27, 2019
Announcement of listing on the NHI drug price standard and marketing of Teribone™ 28.2 µg subcutaneous autoinjector
November 25, 2019
Asahi Kasei to Acquire Veloxis Pharmaceuticals Inc.
November 25, 2019
Asahi Kasei Pharma licenses fasudil to Woolsey Pharmaceuticals
October 30, 2019
Asahi Kasei Pharma to solicit proposals for drug discovery research
October 1, 2019
Filing of Complaint for Injunctive Relief requesting for continuous supply of "XIAFLEX® injection"
September 20, 2019
Approval to manufacture and sell Teribone™ autoinjector
August 2, 2019
Future plan for global Phase III clinical study of ART-123
February 21, 2019
Maruho and Asahi Kasei Pharma Announce First Approval in Japan of an Additional Dosage and Administration for Anti-herpes Virus Agent "Famvir® Tab 250 mg" for the Treatment of Recurrent Herpes Simplex (Herpes labialis/Herpes genitalis)
January 28, 2019
Asahi Kasei Pharma launching legionella kit Ribotest™ Legionella
December 17, 2018
Asahi Kasei Pharma to solicit proposals for drug discovery research
December 11, 2018
Asahi Kasei Pharma launches Kevzara® autoinjector for treatment of rheumatoid arthritis
December 3, 2018
Addition of Kevzara® to category of drugs subject to guidance and management fee for self-injection at home and lift of ban on long-term prescription
October 30, 2018
Application for approval to manufacture and sell Teribone™ autoinjector
August 2, 2018
Preliminary results of overseas Phase III clinical study for ART-123
July 24, 2018
Asahi Kasei Pharma signs distribution agreement with Stanbio Laboratory for the marketing of Lucica® Glycated Albumin-L in the US
Page Top